Abstract: Pharmaceutical compositions comprising anti-C5 antibody are described herein. Methods comprising administering pharmaceutical compositions are described herein. Methods of manufacturing pharmaceutical compositions are described herein.

Abstract: Antibody formulations and methods of making and using such formulations are provided herein. The formulation can be for intravenous administration. In some embodiments, the formulation is for subcutaneous administration. In some embodiments, the formulation comprises an anti-C5 antibody, such as eculizumab.

Abstract: Solid particle aerosol formulations of polypeptide drugs are made by lyophilizing solutions of the drugs which contain milling stabilizers that inhibit degradation of the drug during subsequent milling. The lyophilized drug is milled in fluid energy mills that have been fitted with abrasion-resistant materials and which use pure nitrogen that has been filtered to eliminate particles of greater than 0.1 .mu.m to transport the drug. The use of (a) milling stabilizers in the solution and (b) abrasion-resistant fluid energy mills that use pure filtered nitrogen in the milling step reduce insoluble contaminants and inactive fractions in the milled product.